Product Code: RP-ID-10352037 |
Published Date: 21 Mar 2025 |
Region: Global |
Category: Healthcare & Pharmaceuticals |
Report ID: 10352037
Market Overview:
Cholera Vaccine Market Segmentation by Type (Killed, Whole-Cell Oral Cholera Vaccines, Other Oral Cholera Vaccines); by Product (Dukoral, Shanchol, Vaxchora, Euvichol, and Others)-Global Demand Analysis & Opportunity Outlook 2030
Global Cholera Vaccine Market Highlights over 2022-2030
The global cholera vaccine market is estimated to be approximately USD 68 Million by the end of 2021 and further grow at a CAGR of 7% over the forecast period, i.e., 2022-2030. The growth of the market can be attributed to growing demand for cholera vaccine due to increasing incidences of cholera due to lack of proper sanitation and contaminated food consumption. Moreover, rising awareness regarding cholera and initiatives by public and private healthcare entities towards preventive care and immunization programs are further expected to propel the market growth. For instance, “Ending Cholera—A Global Roadmap to 2030” by the World Health Organisation (WHO) is a global strategy to control cholera that focuses on supporting countries to eliminate the disease transmission and reduce cholera deaths by 90% by 2030.
CLICK TO DOWNLOAD SAMPLE REPORT
Cholera is an acute diarrheal disease, characterized by acute onset watery diarrhea, caused due to water and food contamination led by poor water and sanitation infrastructure. It contains toxigenic strains of the bacterium Vibrio cholerae O1 and O139 and is transmitted through the fecal-oral route. According to the WHO, each year an estimated number of 1.3 to 4.0 million cases of cholera are witnessed globally, with 21,000 to 143,00 deaths.
However, the high cost associated with the development of cholera vaccines resulting in their higher price, leading to unaffordability for patients in developing and under-developed economies is one of the key restraints for the growth of the market. Furthermore, the risk of adverse side effects is also expected to hinder market growth.
The market is segmented by type into killed, whole-cell oral cholera vaccines (WC-OCVs), and other oral cholera vaccines (OCVs). Killed, WC-OCVs is the most widely used cholera vaccines, two doses of which provide protection against cholera for minimum of two years. Owing to this factor, the killed, whole-cell oral cholera vaccines (WC-OCVs) segment is anticipated to hold the largest share of the market over the forecast period. According to Gavi, from 1997 to 2012, just 1.5 million doses of cholera vaccine were used globally, the number of which increased to over 17 million doses alone in 2018.
Based on product, the market is segmented into dukoral, shanchol, vaxchora, euvichol, and others, out of which, dukoral segment is projected to hold the largest market share over the forecast period owing to established global stockpile of this product by the WHO. In addition to that, this product is very popular among travellers and the growing number of people traveling to low and middle-income countries is increasing the demand for this product. Furthermore, the shanchol and euvichol segments are estimated to witness rapid growth during the forecast period owing to the availability for mass vaccination campaigns through the global OCV stockpile.
Global Cholera Vaccine Market Regional Synopsis
Regionally, the global cholera vaccine market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region. The Middle East & Africa region is expected to hold the largest share of the market over the forecast period owing to high demand and deployment of cholera vaccine, especially in countries such as the Democratic Republic of the Congo, Nigeria, and Zimbabwe, on the back of high prevalence of cholera. The number of cholera cases in Africa (including deaths), reported to the World Health Organisation, was 120,652 in 2018, while 12 million doses were used in 9 hotspot countries in Africa in the same year.
The Asia-Pacific region is projected to witness the highest growth during the forecast period owing to increasing demand for vaccines over the growing number of cases of cholera. As per WHO, Yemen recorded the most cholera cases in a single country in 2018 with 371,326 cases, and more than 660,000 doses of OCVs were distributed in the country.
Market Segmentation
Our in-depth analysis of the global cholera vaccine market includes the following segments:
By Type
-
Killed, Whole-Cell Oral Cholera Vaccines (WC-OCVs)
-
Other Oral Cholera Vaccines (OCVs)
By Product
-
Dukoral
-
Shanchol
-
Vaxchora
-
Euvichol
-
Others
Growth Drivers and Challenges Impacting the Growth of the Global Cholera Vaccine Market
Growth Drivers
-
Growing demand for cholera vaccine due to increasing incidences of cholera
-
Rising awareness regarding cholera
-
Initiatives by public and private healthcare entities
Challenges
-
High costs associated with the development of cholera vaccines resulting in their higher price
-
Risk of adverse side effects
Key Companies Dominating the Global Cholera Vaccine Market
Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the global cholera vaccine market that are included in our report are SBL Vaccines, Shantha Biotechnics, EuBiologics Co., Ltd, Emergent BioSolutions Inc., Hilleman Laboratories, Instituto Finlay de Vacunas (IFV), Sanofi, and others.
Latest Developments in the Global Cholera Vaccine Market:
October 2021: BRAC, in coordination with Bangladesh, the World Health Organisation (WHO), and other health partners, facilitated OCV campaign for the Rohingya community as a measure to counter threats of cholera outbreak, the first round of which was carried out from 10th to 25th October 2021.
August 2021: In response to the cholera outbreak in Nigeria since the beginning of 2021, the World Health Organisation (WHO) collaborated with other health authorities and deployed OCVs to prevent the transmission of the disease. Over 700,000 people, over the age of 1 year, were vaccinated in the first cycle that ended on 28th July, 2021
Key Reasons to Buy Our Report
-
The report covers detailed analysis comprising market share attained by each market segment and its sub-segments.
-
It covers market dynamics including growth drivers, trends, potential opportunities, price trend analysis and challenges that impact the market growth.
-
The report includes detailed company profiles of the major players dominating the market.
-
We use effective research methodologies to calculate the market numbers and provide value-added assessment for overall growth.
-
We provide customized reports as per the clients’ requirement helping them to see possible and unexpected challenges and unforeseen opportunities in order to help them reach their goal.
- SBL Vaccines
- Shantha Biotechnics
- EuBiologics Co.Ltd
- Emergent BioSolutions Inc.
- Hilleman Laboratories
- Instituto Finlay de Vacunas (IFV)
- Sanofi
Related Reports
Proof of Quality & Reliability
